ARCHIVES

ODAC Reviews Post-Marketing Studies for Eight Indications

This article is from The Cancer Letter archive.

Vol. 29 No. 08 | February 21, 2003

Download PDF Visit The Full Archive

Related Articles

Lymphoseek Label Updated To Include Head and Neck SCC

June 27, 2014

Controlling Diabetes May Cut Liver Cancer Risk, Study Finds

April 30, 2010

In Brief: McDonnell Foundation Selects Five For $400,000 Fellowships; Alberts, Verma Picked For Awards

January 4, 1991

ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic.

April 9, 2010

NCI “Leadership Vacuum” Deepened?

December 22, 1994

Faulty Estimates Led NCI To Overstate Black-White Cancer Disparity In Atlanta

September 20, 2002